Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong’s perspective

Prostate Cancer and Prostatic Diseases, Published online: 04 July 2019; doi:10.1038/s41391-019-0161-2Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong’s perspective

Source: Prostate Cancer and Prostatic Diseases - July 3, 2019 Category: Urology & Nephrology Authors: Chi Leung Chiang Tsz Him So Tai Chung Lam Horace C. W. Choi Source Type: research